Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed selects MTI institute leader

This article was originally published in The Gray Sheet

Executive Summary

Trade group taps former University of Texas M.D. Anderson Cancer Center VP-International Business Development & Chief Marketing Officer Martyn Howgill to serve as executive director of its newly created Institute for Medical Technology Innovation (1"The Gray Sheet" March 8, 2004, p. 30). Member companies have contributed nearly $12.5 mil. to support the research and education body...

You may also be interested in...



Patient Access, Med Tech Value Research Top Collins’ Goals For AdvaMed

The Institute for Medical Technology Innovation raised just over $11 mil. in the first phase of its development campaign, AdvaMed announced at its annual meeting in Scottsdale, Ariz. March 5

EU Ministers Want Decisive Action On Medicines Access & Shortages

Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.

UsernamePublicRestriction

Register

MT020213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel